A1C reductions seen in therapy combined with metformin
Read More »Empagliflozin May Have Beneficial Long-Term Renal Effects
Empagliflozin might not only decrease the risk of cardiovascular events in patients with type 2, but also renal events.
Read More »Dr. Stanley Schwartz Part 3, Using Evidence-Based Practice
In part 3 of this Exclusive Interview about the new diabetes classification, facilitating the individual use of "evidence-based practice" to individually assess the situation of a specific patient, instead of allowing media supposition about a drug class -- such as SGLT-2s -- to dictate diabetes treatment.
Read More »Type I Diabetes Mellitus: A Triple Therapy Approach
What are the benefits of dapagliflozin for type 1 when added to an insulin-liraglutide regimen?
Read More »SGLT-2s and Evidence-Based Medicine
In this exclusive interview transcript, Dr. Stanley Schwartz discusses SGLT-2s and evidence-based medicine: the risk of DKA in Type 2 diabetes is just five in 10,000, compared to a benefit of 38% reduction in cardiovascular mortality.
Read More »The Philosophy of Blood Sugars
In part 2 of this exclusive interview, Dr. Eckel discusses the new diabetes drugs that offer treatment benefits beyond glucose control, and why 1 + 1 + 1 + 1 may add up to more than 4 when impacting multiple risks.
Read More »Canagliflozin as a Monotherapy in Type 2 Diabetes
Is the SGLT-2 inhibitor best used along with metformin, or is canagliflozin as a monotherapy a good choice?
Read More »Transcript: Dr. Aaron Vinik on What Matters in Studying Bariatric Surgery Outcomes
In this exclusive interview, Dr. Vinik shares his views on what matters in studying bariatric surgery outcomes, and why weight loss and effect on diabetes are not the key questions for him.
Read More »Dr. Aaron Vinik Part 6, T1 and SGLT-2s
Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 6 of this Exclusive Interview, Steve asks Dr. Vinik his opinion on type 1 and SGLT-2s.
Read More »Dr. Aaron Vinik Part 5, The Hesitancy to Use New Drugs
Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 5 of this Exclusive Interview, Dr. Vinik explains the caution on the part of doctors to use the latest SGLT-2 medications despite apparent benefits.
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.